Birdwatch Note
2024-10-21 00:35:16 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
動画40秒の自分がコロナワクチンので悪性リンパ腫になったとの主張ですが、 コロナワクチンのそうしたリスクは米国立がん研究所にも把握されてません。 https://www.cancer.gov/about-cancer/coronavirus/covid-19-vaccines-people-with-cancer# その上で悪性リンパ腫の年間死亡推移は下記で、コロナ禍で何の影響にせよ、動態に異常が見られる疾患ではありません。 https://medicalfacts.info/cod.rb?l=ja&years=2013~2014~2015~2016~2017~2018~2019~2020~2021~2022~2023&ages=all&sex=both&graph_type=yearly_reg_2019&top=none&columns=3&death_codes=all~02118~02201&align_max=&per_capita=&adjusted=&i=false 悪性リンパ腫は21,22年も全がん登録数の3.8%,3.7%で17-20年の3.6～3.8%の値の推移と全く変わりませんし(↓表3-7-1 https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2022_report.pdf https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2021_report_02.pdf 21,22年の全がん登録数の増加傾向も検診の減少の続いている事もあるかと思いますが、コロナ前の増加傾向より大幅に少ないままです(↓図2-1 https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2022_report.pdf
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1848149158051684609
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1848161091546988921
- noteId - 1848161091546988921
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1729470916054
- tweetId - 1848149158051684609
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 動画40秒の自分がコロナワクチンので悪性リンパ腫になったとの主張ですが、 コロナワクチンのそうしたリスクは米国立がん研究所にも把握されてません。 https://www.cancer.gov/about-cancer/coronavirus/covid-19-vaccines-people-with-cancer# その上で悪性リンパ腫の年間死亡推移は下記で、コロナ禍で何の影響にせよ、動態に異常が見られる疾患ではありません。 https://medicalfacts.info/cod.rb?l=ja&years=2013~2014~2015~2016~2017~2018~2019~2020~2021~2022~2023&ages=all&sex=both&graph_type=yearly_reg_2019&top=none&columns=3&death_codes=all~02118~02201&align_max=&per_capita=&adjusted=&i=false 悪性リンパ腫は21,22年も全がん登録数の3.8%,3.7%で17-20年の3.6～3.8%の値の推移と全く変わりませんし(↓表3-7-1 https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2022_report.pdf https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2021_report_02.pdf 21,22年の全がん登録数の増加傾向も検診の減少の続いている事もあるかと思いますが、コロナ前の増加傾向より大幅に少ないままです(↓図2-1 https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2022_report.pdf
Note Ratings
| rated at | rated by | |
| 2024-10-22 10:06:15 -0500 | Rating Details | |
| 2024-10-22 01:56:10 -0500 | Rating Details | |
| 2024-10-21 05:48:18 -0500 | Rating Details | |
| 2024-10-21 04:46:13 -0500 | Rating Details | |
| 2024-10-21 03:03:36 -0500 | Rating Details | |
| 2024-10-21 02:43:33 -0500 | Rating Details | |
| 2024-10-21 02:01:20 -0500 | Rating Details | |
| 2024-10-21 01:44:01 -0500 | Rating Details | |
| 2024-10-21 00:55:56 -0500 | Rating Details | |
| 2024-10-21 00:26:09 -0500 | Rating Details | |
| 2024-10-20 22:38:15 -0500 | Rating Details | |
| 2024-10-20 22:37:30 -0500 | Rating Details | |
| 2024-10-20 22:12:36 -0500 | Rating Details | |
| 2024-10-20 21:48:23 -0500 | Rating Details | |
| 2024-10-20 21:41:37 -0500 | Rating Details | |
| 2024-10-20 20:47:06 -0500 | Rating Details | |
| 2024-10-20 20:42:25 -0500 | Rating Details | |
| 2024-10-20 20:23:15 -0500 | Rating Details | |
| 2024-10-20 20:11:49 -0500 | Rating Details | |
| 2024-10-20 20:07:54 -0500 | Rating Details | |
| 2024-10-20 20:07:39 -0500 | Rating Details | |
| 2024-10-20 20:02:45 -0500 | Rating Details | |
| 2024-10-24 20:38:09 -0500 | Rating Details | |
| 2024-10-21 12:29:52 -0500 | Rating Details | |
| 2024-10-21 04:55:45 -0500 | Rating Details | |
| 2024-10-21 03:49:15 -0500 | Rating Details | |
| 2024-10-21 03:13:10 -0500 | Rating Details | |
| 2024-10-21 02:52:29 -0500 | Rating Details | |
| 2024-10-21 02:31:01 -0500 | Rating Details | |
| 2024-10-21 01:16:45 -0500 | Rating Details | |
| 2024-10-21 00:57:16 -0500 | Rating Details | |
| 2024-10-21 00:41:12 -0500 | Rating Details | |
| 2024-10-20 23:22:16 -0500 | Rating Details | |
| 2024-10-20 23:15:49 -0500 | Rating Details | |
| 2024-10-20 21:55:49 -0500 | Rating Details | |
| 2024-10-20 21:29:46 -0500 | Rating Details | |
| 2024-10-20 21:27:15 -0500 | Rating Details | |
| 2024-10-20 21:03:28 -0500 | Rating Details | |
| 2024-10-20 20:38:10 -0500 | Rating Details | |
| 2024-10-20 20:10:52 -0500 | Rating Details | |
| 2024-10-20 20:08:32 -0500 | Rating Details | |
| 2024-10-20 20:07:15 -0500 | Rating Details | |
| 2024-10-20 20:03:48 -0500 | Rating Details | |
| 2024-10-20 19:52:44 -0500 | Rating Details | |
| 2024-10-20 19:51:02 -0500 | Rating Details | |
| 2024-10-21 19:50:36 -0500 | Rating Details | |
| 2024-10-21 19:16:43 -0500 | Rating Details | |
| 2024-10-21 09:44:20 -0500 | Rating Details | |
| 2024-10-21 06:48:55 -0500 | Rating Details | |
| 2024-10-21 03:44:32 -0500 | Rating Details | |
| 2024-10-21 03:44:30 -0500 | Rating Details | |
| 2024-10-21 03:21:17 -0500 | Rating Details | |
| 2024-10-21 00:36:44 -0500 | Rating Details | |
| 2024-10-21 00:19:53 -0500 | Rating Details | |
| 2024-10-20 23:54:12 -0500 | Rating Details | |
| 2024-10-20 23:16:51 -0500 | Rating Details | |
| 2024-10-20 23:08:11 -0500 | Rating Details | |
| 2024-10-20 23:07:28 -0500 | Rating Details | |
| 2024-10-20 22:23:50 -0500 | Rating Details | |
| 2024-10-20 22:01:37 -0500 | Rating Details | |
| 2024-10-20 21:57:15 -0500 | Rating Details | |
| 2024-10-20 21:35:50 -0500 | Rating Details | |
| 2024-10-20 20:54:01 -0500 | Rating Details | |
| 2024-10-20 19:58:24 -0500 | Rating Details | |
| 2024-10-20 19:57:49 -0500 | Rating Details | |
| 2024-10-20 19:56:35 -0500 | Rating Details | |
| 2024-10-20 19:53:28 -0500 | Rating Details | |
| 2024-10-26 12:45:50 -0500 | Rating Details | |
| 2024-10-21 23:07:38 -0500 | Rating Details | |
| 2024-10-21 19:52:21 -0500 | Rating Details | |
| 2024-10-21 08:54:24 -0500 | Rating Details | |
| 2024-10-21 06:12:55 -0500 | Rating Details | |
| 2024-10-21 04:09:22 -0500 | Rating Details | |
| 2024-10-21 02:31:23 -0500 | Rating Details | |
| 2024-10-21 00:25:21 -0500 | Rating Details | |
| 2024-10-20 23:16:13 -0500 | Rating Details | |
| 2024-10-20 23:03:23 -0500 | Rating Details | |
| 2024-10-20 22:25:50 -0500 | Rating Details | |
| 2024-10-20 21:48:25 -0500 | Rating Details | |
| 2024-10-20 21:02:23 -0500 | Rating Details | |
| 2024-10-20 20:44:25 -0500 | Rating Details | |
| 2024-10-20 20:38:25 -0500 | Rating Details | |
| 2024-10-20 20:17:43 -0500 | Rating Details | |
| 2024-10-20 20:01:31 -0500 | Rating Details | |
| 2024-10-20 19:57:41 -0500 | Rating Details | |
| 2024-10-20 19:52:31 -0500 | Rating Details | |
| 2024-10-27 14:45:44 -0500 | Rating Details | |
| 2024-10-21 20:08:20 -0500 | Rating Details | |
| 2024-10-21 18:39:07 -0500 | Rating Details | |
| 2024-10-21 04:43:16 -0500 | Rating Details | |
| 2024-10-21 04:31:14 -0500 | Rating Details | |
| 2024-10-21 03:17:39 -0500 | Rating Details | |
| 2024-10-21 01:53:43 -0500 | Rating Details | |
| 2024-10-21 01:19:22 -0500 | Rating Details | |
| 2024-10-21 01:11:01 -0500 | Rating Details | |
| 2024-10-21 00:14:10 -0500 | Rating Details | |
| 2024-10-20 23:55:08 -0500 | Rating Details | |
| 2024-10-20 23:53:04 -0500 | Rating Details | |
| 2024-10-20 23:23:50 -0500 | Rating Details | |
| 2024-10-20 22:43:07 -0500 | Rating Details | |
| 2024-10-20 22:10:38 -0500 | Rating Details | |
| 2024-10-20 22:10:04 -0500 | Rating Details | |
| 2024-10-20 21:23:27 -0500 | Rating Details | |
| 2024-10-20 21:07:55 -0500 | Rating Details | |
| 2024-10-20 20:08:03 -0500 | Rating Details | |
| 2024-10-20 20:04:34 -0500 | Rating Details | |
| 2024-10-20 20:01:21 -0500 | Rating Details | |
| 2024-10-20 19:59:14 -0500 | Rating Details | |
| 2024-10-20 19:57:45 -0500 | Rating Details | |
| 2024-10-20 19:55:58 -0500 | Rating Details |